Consequently, specific deletion of HDAC6 in total CD4+ T cells resulted in stronger antitumor response and HCC tumor rejection upon anti–PD-1 treatment in mice, although this effect was only partially attributable to IL-17 (62). This evidence concerns the gene HDAC6 and neoplasm.